


Reduced Coinsurance for Certain Part B Rebatable Drugs under the Medicare Prescription Drug Inflation Rebate Program



Applicable April 1 – June 30, 2023

President Biden's historic Inflation Reduction Act requires drug companies to pay rebates to Medicare when prescription drug prices increase faster than the rate of inflation for certain drugs furnished to people with Medicare. This new inflation rebate applies to Medicare Part B rebatable drugs, which are single source drugs and biological products, including certain biosimilar biological products, beginning January 1, 2023.

The federal government intends to invoice drug manufacturers for 2023 and 2024 Part B inflation rebates no later than fall 2025. The rebates will be deposited into the Medicare Trust Fund. In addition, beginning April 1, 2023, people with Medicare may see lower out-of-pocket costs for certain Part B drugs and biologicals with prices that have increased faster than the rate of inflation. For these drugs and biologicals, the beneficiary coinsurance will be 20% of the inflation-adjusted payment amount, which will be less than what the beneficiary would pay in coinsurance otherwise.

CMS posts payment information each quarter for separately payable Part B drugs, including the Part B rebatable drugs subject to the coinsurance adjustments, in the Medicare Part B Quarterly Sales Pricing (ASP) file, which is publicly available on CMS.gov. For the first time, the April 2023 ASP public file will also include the coinsurance adjustments for certain Part B rebatable drugs as required by the Inflation Reduction Act. The Part B drugs impacted by a coinsurance adjustment may change quarterly.

For the time period of April 1 to June 30, 2023, 27 Part B rebatable drugs have an adjusted coinsurance rate based on the inflation-adjusted payment amount. People with Traditional Medicare and Medicare Advantage who use these drugs may, depending on other health coverage they may have, pay a reduced amount for their coinsurance during this specific quarter. For the quarter April 1-June 30, 2023, people with Medicare may experience coinsurance amounts that are lower than what they would have paid before the new law passed by as much as \$2 to \$390 per average dose.

Below is the list of drugs with adjusted coinsurance amounts for the quarter April 1-June 30, 2023. Learn more about the Medicare Prescription Drug Inflation Rebate Program here. A fact sheet on the Part B rebatable drug coinsurance reduction is available here: **Medicare Prescription Drug Inflation Rebates Program**

HCPSC Code	Short Description	Inflation-Adjusted Coinsurance Percentage (Normally 20.000%)
J0287	Abelcet	19.180%
J8655	Akynzeo	16.213%
J7504	Atgam	17.830%
J3145	Aveed	19.239%
J0558	Bicillin C-R	18.921%
J0561	Bicillin L-A	18.514%

HCPCS Code	Short Description	Inflation-Adjusted Coinsurance Percentage (Normally 20.000%)
J1955	Carnitor	13.918%
J0850	Cytogam	18.983%
J9269	Elzonris	19.969%
J0699	Fetroja	10.274%
J1572	Flebogamma DIF	17.655%
J9307	Folotyn	19.965%
J1645	Fragmin	13.995%
J0135	Humira	19.529%
J2820	Leukine	19.648%
J2265	Minocin	19.288%
J0888	Mircera	17.614%
J9268	Nipent	17.269%
J9177	Padcev	19.470%
J9061	Rybrevant	19.747%
J2502	Signifor LAR	18.406%
J2860	Sylvant	19.777%
Q2053	Tecartus	19.958%
J2792	Winrho SDF	19.882%
J0775	Xiaflex	18.960%
J3299	Xipere	18.969%
Q2041	Yescarta	19.937%